Last reviewed · How we verify

Candidemia and Invasive Candidiasis — Treatment Landscape & Competitive Intelligence

Candidemia and Invasive Candidiasis (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Candidemia and Invasive Candidiasis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Isauvuconazole group isauvuconazole-group Pfizer Echinocandin β-(1,3)-D-glucan synthase Not yet launched

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Pfizer · 1 drug in Candidemia and Invasive Candidiasis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Candidemia and Invasive Candidiasis:

Cite this brief

Drug Landscape (2026). Candidemia and Invasive Candidiasis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/candidemia-and-invasive-candidiasis. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing